NEW YORK (GenomeWeb) – Invitae said today that it has acquired health software developer Ommdom and its genomic management tool CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories.
Under the terms of the agreement, Invitae acquired all Ommdom's outstanding capital stock in exchange for approximately $6 million in Invitae common stock.
According to Invitae, the acquisition expands its existing suite of technologies that help patients and clinicians use genetic information as part of mainstream medical care.
"The CancerGene Connect platform is unmatched for ease of use and depth of analysis, and has strong endorsement from clinicians who use it," Invitae CEO Sean George said in a statement.
Initially developed at UT Southwestern, CancerGene Connect is a cloud-based, mobile-friendly patient interface that prompts and guides users to gather their family history information prior to an appointment with a clinician.
Once an individual completes entering their information, clinicians can then use the platform to evaluate hereditary risk, analyze a patient's predisposition to disease, and make decisions about further genetic testing or medical treatment. Physicians can also access data and study trends across all their patients that have used the portal.